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Objective: In patients with clinical T1 N0 M0 lung adenocarcinoma, we investigated
whether the proportion of ground-glass opacity area measured on high-resolution
computed tomography was valuable for predicting the existence of lymph node
metastasis, lymphatic invasion, or vascular invasion.
Methods: Between 1994 and 1999, 111 patients with clinical stage IA adenocarci-
noma underwent surgical resection of the lung at our hospital. Of these, 96 patients
received high-resolution computed tomography of the chest, and they constituted
the study population. The tumors were semiquantitatively classified into 5 groups on
the basis of the proportion of ground-glass opacity area to whole tumor shadow on
high-resolution computed tomography: group I, 0%; group II, 1% to 25%; group III,
26% to 50%; group IV, 51% to 75%; and group V, 76% to 100%. Correlations of
computed tomographic findings, pathologic results of lymph node metastasis and
lymphatic and vascular invasion, and the histologic subtype according to the new
World Health Organization classification were examined. We also investigated
the characteristics of the patients with ground-glass opacity areas on high-
resolution computed tomography and their value for predicting lymph node
metastasis.
Results: Among the 96 patients, 15 (15.6%) had mediastinal lymph node metastases,
and 3 (3.1%) had hilar node metastases. Regarding the proportion of the ground-
glass opacity area of the tumors, 15 (15.6%) tumors were classified as group V, 11
(11.5%) as group IV, 9 (9.3%) as group III, 22 (22.9%) as group II, and 39 (40.6%)
as group I, respectively. Of the 18 patients with lymph node metastases, no patients
were found in groups IV and V, 2 (22.2%) were found in group III, 4 (18.2%) were
found in group II, and 12 (30.8%) were found in group I (trend P  . 003),
respectively. Twenty-six patients classified into groups IV and V also showed
neither lymphatic invasion nor recurrence. All the smaller tumors (2.0 cm) in
group IV or V were histologically proved to be bronchioloalveolar carcinoma.
Adjusted for smoking status and other characteristics, patients without ground-glass
opacity on high-resolution computed tomography had a significantly increased risk
of concurrent lymph node metastasis compared with those with ground-glass
opacity.
Conclusion: In patients with clinical T1 N0 M0 adenocarcinoma, the proportion of
ground-glass opacity area on thin-section computed tomography scans was a strong
predictor for tumor aggressiveness and thus could be a useful index for planning
limited surgical resection for these patients.
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There have been two concerns regarding op-erations for patients with clinical stage IAnon-small cell lung cancer: one is to whatextent the lymph node area should be dis-sected, and the other is the volume of thelung parenchyma that should be resected.
Many surgeons advocate that systematic nodal dissection be
routinely used for accurate intrathoracic staging of non-
small cell lung cancer, even if a patient’s disease is classi-
fied as clinical stage IA, because no clinical or pathologic
subset of patients with a negligible incidence of N2 disease
has been discriminated.1-3 On the basis of the results of a
prospective randomized trial comparing limited resection
with lobectomy for the management of patients with T1 N0
disease, limited resection should not be recommended as the
treatment of choice for these patients because of the high
incidence of local recurrence.4
Recently, the advent of high-resolution computed tomog-
raphy (HRCT) has made it possible to investigate tumor
shadows in more detail. Some cases of adenocarcinoma
showed ground-glass opacity (GGO) at the tumor periphery
that reflected the lepidic growth of the tumor cells seen in
bronchioloalveolar carcinoma (BAC) microscopically.5
Moreover, patients with peripheral adenocarcinoma accom-
panied by a high BAC component showed better progno-
sis.6,7 Therefore, we reviewed HRCT scans of patients with
cT1 N0 M0 peripheral adenocarcinoma to determine the
value of the presence and extent of areas of GGO as a
clinicopathologic indicator, especially for the extent of
nodal involvement and the presence of intratumoral lym-
phatic and vascular invasion of tumor cells, which might
reflect tumor aggressiveness.8-10 We also investigated a
correlation between the proportion of GGO on HRCT and
histologic findings of the tumors and characteristics of pa-
tients with GGO.
Patients and Methods
Between October 1994 and December 1999, 370 patients with
primary lung cancer underwent surgical resection of the lung at our
hospital. Of these, 130 patients were given a diagnosis of clinical
stage IA disease, of whom 111 patients had adenocarcinoma.
Among the patients, 96 received HRCT, and they constituted the
study population. All patients underwent physical examination,
chest radiography, bone scintigraphy, bronchoscopic examination,
and magnetic resonance imaging of the brain, as well as CT of the
chest and upper part of the abdomen for staging and evaluation of
resectability before the operation. Serum levels of tumor markers
associated with adenocarcinoma of the lung, such as carcinoem-
bryonic antigen (normal range,  5 ng/mL), carbohydrate antigen
19-9 (37 U/mL), and sialyl Lewis(x) (38 U/mL), were ana-
lyzed preoperatively.
Fifty-seven patients were women, and the mean age was 61.6
years (range, 40-80 years). For cigarette smoking, patients who
never smoked and those who ever smoked numbered 53 and 43,
respectively. Surgical treatment was performed as follows: pneu-
monectomy in 1 patient, lobectomy in 79 patients, segmentectomy
in 11 patients, and partial resection in 5 patients. A patient with
pleural disseminated disease underwent an extrapleural pneumo-
nectomy. Systematic lymph node dissection was performed in 77
patients, whereas sampling or no resection of mediastinal lymph
nodes was done in 19 patients in whom no node metastasis was
clinically suspected. Of those 19 patients, 9 underwent intention-
ally limited operations without systematic nodal dissection be-
cause of the tumor’s less aggressive appearance, and consequently,
none of these tumors have recurred. The remaining 10 patients did
not undergo complete nodal staging because of the impaired con-
dition.
The tumors were classified into 3 histologic subtypes according
to the classification of the World Health Organization (WHO),
with some modification: BAC, BAC with small invasive foci (5
mm), and other subtypes, including acinar, papillary, solid carci-
noma with mucin, and adenocarcinoma with mixed subtype.11
BAC was defined as an adenocarcinoma with a pure bronchioloal-
veolar growth pattern and no evidence of stromal, vascular, or
pleural invasion. Stromal invasion is suggested by tumor cells
arranged in acinic, papillotubular structures or solid tumor cells in
a fibroblastic stroma, often accompanied by collagenization. BACs
with invasive foci  5 mm in diameter were classified as BAC
with small invasive foci. If invasive foci were larger than 5 mm,
the tumors were classified into other subtypes. Pathologic stage
was classified according to the International System for Staging
Lung Cancer criteria.12
CT scanning was performed on a TCT 900S (Toshiba Medical
Systems, Tokyo, Japan) or X-Vigor (Toshiba Medical Systems)
scanner. HRCT scans were performed over a range of 50 mm,
covering the entire lesion. The scanning parameters were a tube
voltage of 120 kV, a tube current of 250 mA, 2-mm collimation,
table speed of 2 mm/s, 1 rotation per second, pitch of 1, and a
reconstruction interval of 2 mm by using a bone algorithm. The
field of view was focused at about 20 cm in 60 patients. The
images were photographed with a window level of 650 HU and
a window width of 1800 HU. The analysis was made on hard-copy
films. GGO was defined as a hazy increase in lung attenuation
without obscuring the underlying vascular marking. In this study
we defined GGO as reflection of a tumor cell lepidic growth
pattern seen in BAC. Therefore, the area we thought to be sec-
ondary inflammation was not regarded as GGO. Three observers
who were unaware of the pathologic staging and prognosis re-
viewed each HRCT scan of 96 peripheral adenocarcinomas and
quantitated the percentage of lesions occupied by areas of GGO on
all slices on which the tumor appeared visually. Then, according to
the proportion of the GGO area, we classified the tumors into 5
groups: group I, 0%; group II, 1% to 25%; group III, 26% to 50%
(Figure 1); group IV, 51% to 75%; and group V, 76% to 100%
(Figure 2). Discrepancies in interpretation between observers were
resolved by consensus. The reasons we estimated the proportion of
GGO on all slices on which a tumor existed instead of on one level
of the tumor equator were as follows. First, we thought that it was
easier to classify each tumor into the 5 categories by considering
more information than from one slice. Second, because the distri-
bution of GGO was not uniform around the solid portion, all slices
were superior to one slice for expressing the tumor characteristics.
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All lesions were surgically resected within 2 months or less
after CT examination. Four-micrometer sections, including the
largest piece cut from the surface of the tumor in each case, were
stained with hematoxylin and eosin and elastica van Gieson stains
and examined by means of light microscopy. Intratumoral vascular
invasion was determined by means of the identification of tumor
cells in blood vessels. Lymphatic invasion was also morphologi-
cally distinguished from vascular invasion. The patients were
scheduled for checkups, chest radiography, and measurement of
tumor marker serum levels every 1 to 3 months for 2 years after the
operation and every 6 months thereafter. All patients except one
were followed up until death or the last date of the follow-up
(March 31, 2001). The average length of follow-up was 40 months.
We investigated the association of the proportion of GGO area
with maximal tumor size, lymph node metastasis, lymphatic inva-
sion, vascular invasion, and the histologic subtype according to the
new WHO classification. We also examined the characteristics of
patients having a greater proportion of GGO area and the GGO
classification in relation to the prediction of lymph node metasta-
sis. The Mantel-Haenszel 2 test was performed to examine cor-
Figure 1. A, HRCT showing group III tumor according to the GGO classification. B, Histologic specimen showing
the tumor had an invasive area >5 mm in diameter and BAC component.
Figure 2. A, HRCT showing group V tumor according to the GGO classification. B, Histologic specimen showing the
tumor was composed of BAC growth pattern with no evidence of invasion.
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relations between the proportion of GGO and clinicopathologic
factors. We also examined a relation of lymph node metastasis
with selected characteristics. To further clarify the independent
factors in association with lymph node metastasis, we performed
multiple logistic regression analysis with the SAS software pack-
age (Statistical Analysis Systems, Inc, Cary, NC).
Results
Pathologic examination revealed that 21.8% of the tumors
were BACs, and 10.4% were BACs with small invasive
foci. T1 tumors were found in 90.6% of the patients,
whereas T2 and T4 tumors were discovered in 5 and 4
patients, respectively. Mediastinal lymph node metastasis
was found in 15 (15.6%) patients, and hilar node metastasis
was found in 3 (3.1%) patients.
During the follow-up period, 23 patients had tumor re-
currences. Of the 16 patients with locoregional relapse, 4
with pathologic N2 disease had lymph node recurrences
beyond the dissected area of the mediastinum. No nodal
recurrence was observed in patients with pathologic N0
disease.
Among the 96 tumors, 15 (15.6%) were classified as
group V, 11 (11.5%) as group IV, 9 (9.3%) as group III, 22
(22.9%) as group II, and 39 (40.6%) as group I according to
the proportion of GGO area. The distribution of pathologic
N status and vessel invasion by proportion of GGO and
maximal tumor diameter are shown in Table 1. The numbers
of node-positive cases were 0 (0%) for groups V and IV, 2
(22.2%) for group III, 4 (18.2%) for group II, and 12
(30.8%) for group I, respectively. Among the patients with
group V and IV tumors, no resected tumors showed lym-
phatic or vascular invasion, with the exception of one pa-
tient with a relatively large tumor (2 cm) with vascular
invasion. The patients in groups I, II, and III had several
occurrences of lymph node metastasis and lymphatic and
vascular invasion. According to the tumor size, only 5
(5.2%) tumors measuring  1 cm were accompanied with
neither lymph node metastasis nor vessel invasion. On the
other hand, lymph node metastasis was more often observed
in patients with tumors larger than 1 cm in diameter. Except
for the smallest tumors with a diameter  1 cm, the pro-
portion of each GGO group was not different among the
other 3 groups (P  .80).
The relationship between the proportion of GGO and
patient and tumor characteristics is shown in Table 2. BACs
and BACs with small foci of invasion were found in 93% of
group V patients, 82% of group IV patients, 33% of group
III patients, 14% of group II patients, and 5% of group I
patients. In patients with tumors 2 cm in diameter, all
tumors in group IV and V patients were BACs. All patients
classified as having BAC or BAC with minimal invasive
foci are alive without recurrence.
Women, patients who never smoked, and patients with a
normal range of preoperative tumor marker values had a
significantly greater portion of GGO, whereas nodal in-
volvement, lymphatic invasion, and vascular invasion were
observed more often among those with a smaller proportion
of GGO (Table 2).
A multiple logistic regression analysis revealed that ab-
sence of GGO area on CT was an independent risk factor for
lymph node metastasis (odds ratio, 4.87; 95% confidence
interval, 1.51-15.77; Table 3). In 77 patients with complete
nodal staging, the analysis also showed basically the same
results (odds ratio, 4.24; 95% confidence interval, 1.17-
15.38).
Discussion
Among patients with clinical T1 N0 M0 peripheral adeno-
carcinoma, the proportion of GGO area in the tumor shadow
was related to aggressiveness of the tumor independent of
tumor size. This finding will become an important factor
when planning appropriate surgical treatment, especially
less invasive surgical intervention.
TABLE 1. Relationship among GGO classification, maximal tumor diameter, nodal status, and vessel invasion
Total
Nodal status Vessel invasion
N0 N1 N2 ly v
GGO classification
V 15 15 (100) 0 (0) 0 (0) 0 (0) 0 (0)
IV 11 11 (100) 0 (0) 0 (0) 0 (0) 1 (9.1)
III 9 7 (77.8) 1 (11.1) 1 (11.1) 0 (0) 2 (22.2)
II 22 18 (81.8) 2 (9.1) 2 (9.1) 5 (22.7) 7 (31.8)
I 39 27 (69.2) 0 (0) 12 (30.8) 13 (33.3) 13 (33.3)
Maximal tumor diameter (cm)
1.0 5 5 (100) 0 (0) 0 (0) 0 (0) 0 (0)
1.1-1.5 14 12 (85.7) 0 (0) 2 (14.3) 2 (14.3) 4 (28.6)
1.6-2.0 18 15 (83.3) 0 (0) 3 (16.7) 3 (16.7) 3 (16.7)
2.1-3.0 59 46 (80.0) 3 (5.1) 10 (17.0) 13 (22.0) 16 (27.1)
Total 96 78 (81.3) 3 (3.1) 15 (15.6) 18 (18.8) 23 (24.0)
Numbers in parentheses indicate percentages. ly, Lymphatic invasion; v, vascular invasion.
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Including thoracoscopic surgery, limited surgical resec-
tion might have some advantages over a standard operation
for selected patients.13 However, patient selection was dif-
ficult because several studies revealed that mediastinal
lymph node metastasis was common in patients with small
peripheral adenocarcinomas.1-2 Therefore, if the tumor is
larger than 1 cm in diameter, lobectomy with systematic
lymph node dissection is now recommended as the standard
treatment, with the aim of accurate staging and possible
improvement of prognosis. On the other hand, patients with
a tumor 1 cm rarely have lymph node metastasis.2 Yo-
shida and colleagues3 found only 13 (1.2%) such cases
among 1051 patients with lung cancer who underwent sur-
gical resection. The proportion of these small tumors was
only about 5% of clinical T1 N0 M0 cases and 0.8% of all
surgically treated cases in our study. Therefore, a more
reliable and useful indicator for predicting the possibility of
lymph node metastasis in this clinical stage is desirable.
Shimosato and associates14 noted a poorer prognosis in
patients with an increased amount of collagenization or
hyalinization in the central fibrotic focus in the tumor. As
results of analyses of various prognostic factors in resected
cases, it has been shown that the size of the central fibrotic
area relates to outcome in patients with adenocarcinoma.6,15
From a different point of view, Higashiyama and cowork-
ers7 suggested that the degree of BAC involvement might
reflect clinicopathologic and prognostic characteristics. In
1996, Jang and colleagues16 reported that GGO in BAC on
thin-section CT was an early sign of BAC. In addition, the
extent of GGO might be well correlated with that of bron-
chioloalveolar growth of lung adenocarcinoma.5 Therefore,
we classified the tumors according to the proportion of
GGO in the tumor shadow on HRCT and confirmed that the
patients with a higher proportion of GGO had a tendency for
their tumors not to metastasize to the lymph nodes. There
were 26 (27%) patients with a higher proportion of GGO
TABLE 2. Relationship between the proportion of GGO and patient and tumor characteristics
GGO group
P value for trendV IV III II I Total
Sex
Male 3 2 4 9 21 39
Female 12 9 5 13 18 57 .008
Age
62 y 7 3 2 13 19 44
62 y 8 8 7 9 20 52 .341
Smoking status
Never 11 9 5 12 16 53
Ever 4 2 4 10 23 43 .007
Tumor marker
Normal range 14 8 8 14 22 66
High* 1 3 1 8 17 30 .006
Tumor size
2.0 cm 8 3 2 7 17 37
2.0 cm 7 8 7 15 22 59 .917
Nodal involvement
N0 15 11 7 18 27 78
N1-2 (N1) 0 0 2 (1) 4 (2) 12 18 (3) .003
Lymphatic invasion
Negative 15 11 9 17 26 78
Positive 0 0 0 5 13 18 .001
Vascular invasion
Negative 15 10 7 15 26 73
Positive 0 1 2 7 13 23 .004
Histological subtype
BAC 12 (8) 6 (3) 1 (0) 1 (0) 1 (0) 21 (11)
BAC invasive† 2 (0) 3 (0) 2 (1) 2 (0) 1 (0) 10 (1)
Other 1 (0) 2 (0) 6 (1) 19 (7) 37 (17) 65 (25) .001‡
Recurrence
No 15 11 8 16 23 73
Yes 0 0 1 6 16 23 .001
Numbers in parentheses were cases of the tumor 2 cm in diameter or less.
*At least one tumor marker was elevated over the normal range (carcinoembryonic antigen, 5 ng/mL; carbohydrate antigen 19-9, 37 U/mL; and sialyl
Lewis(x), 38 U/mL).
†BAC with small invasive foci (5 mm).
‡Relationship between the proportion of GGO and histologic subtype (BAC vs BAC invasive  other).
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(51%-100%), and they did not have lymph node metastasis
or evidence of tumor recurrence. We believe that the pro-
portion of GGO was a powerful indicator of lymph node
metastasis and a powerful indicator for identifying patients
suitable for limited resection.
The Lung Cancer Study Group reported the results of a
prospective randomized trial comparing limited resection
with lobectomy for the management of patients with T1
N0.4 A total of 247 patients were eligible for analysis. The
limited resection group had a significantly higher local
recurrence rate than the lobectomy group. The Lung Cancer
Study Group therefore concluded that limited resection
should not be recommended as the resection of choice for
patients with T1 N0 disease. Ichinose and associates17 re-
ported that 44% of tumors showed lymphatic invasion in
patients with resected non-small cell lung cancers classified
as pathologic stage I located on the periphery of the lung.
They speculated that this was the main reason that the
limited resection group had a higher local recurrence rate in
the Lung Cancer Study Group trial. Others reported that
lymphatic vessel invasion was correlated with poorer prog-
nosis in patients with non-small cell lung cancer.9 This
suggested that intratumoral lymphatic invasion reflected
tumor aggressiveness. Therefore, if we could select patients
with tumors without lymphatic invasion, limited resection
might be successfully performed without local recurrence.
In our series tumors with a proportion of GGO greater than
50% did not show lymphatic invasion. According to the new
WHO classification, BAC was defined as not showing in-
vasive foci including vessel invasion.11 In this study all the
tumors that measured  2 cm in groups IV and V were
histologically diagnosed as BAC. Tumors larger than 2 cm
in diameter classified in group IV and V were found in 7
patients with BAC and 8 patients with BAC plus invasive
foci. However, those 15 patients had neither lymphatic
invasion nor nodal metastasis and are alive without recur-
rence. Therefore, we consider that patients with T1 tumors
categorized to groups IV and V are candidates for limited
resection. Meanwhile, it should be argued whether intraop-
erative pathologic examination would be useful to indicate
a limited resection for a favorable BAC. Yamato and col-
leagues18 proposed limited resection for BAC on the basis
of the intraoperative pathologic examination. They con-
verted wedge resection into lobectomy if active fibroblastic
foci or invasive signs were presented on the frozen section.
However, it is still unclear whether BACs with small inva-
sive foci are not candidates for limited resection. Further
studies will be necessary to clarify this issue.
Recently, positron emission tomography (PET) was in-
troduced for mediastinal staging. It was shown to have a
high percentage of negative predictive value in patients with
stage I disease.19 PET might provide more accurate lymph
node staging than CT. However, it might not provide infor-
mation on lower tumor invasiveness that could be obtained
by GGO classification. Higashi and associates20 reported
that Fluorine-18-FDG PET imaging results were negative in
4 of 7 patients with BAC and 1 of 23 patients without
BAC.20 Although these results showed that PET could be
TABLE 3. Relationships among selected characteristics and risk of concurrent lymph node metastasis
Factors
Lymph node metastasis
Odds ratio* 95% CI P value 
Sex
Male 32 7 1.00 Reference —
Female 46 11 0.86 0.12-5.93 .89
Smoking status
Never 43 10 1.00 Reference —
Ever 35 8 0.81 0.12-5.39 .83
Tumor marker
Normal 53 13 1.00 Reference —
High† 25 5 0.60 0.18-2.03 .41
Tumor size
1.0 cm 5 0 1.65‡ 0.58-4.68 .35
1.1-1.5 cm 12 2
1.6-2.0 cm 15 3
2.1-3.0 cm 46 13
GGO
Present 51 6 1.00 Reference —
Absent 27 12 4.87 1.51-15.77 .01
CI, Confidence interval.
*Adjusted for other characteristics in the Table.
†At least one tumor marker was elevated over the normal range (carcinoembryonic antigen 5 ng/mL; carbohydrate antigen 19-9, 37 U/mL; and sialyl
Lewis(x), 38 U/mL).
‡An increased risk due to a 1-cm increase in diameter.
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used to diagnose some cases of BAC, we consider that PET
is more expensive and not as accessible as CT. We believe
that GGO classification on HRCT could be more useful than
PET for planning limited operations.
In conclusion, by using this novel classification based on
semiquantitative analysis of the GGO area in the tumor
shadow on HRCT, we identified patients with less invasive
tumors. Thus, it could be a useful tool for planning thera-
peutic strategies, particularly for limited surgical interven-
tion.
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